StockpollyBeta
Get App
Popularity #2,677
RLMD · NASDAQ · Biotechnology

Relmada Therapeutics (RLMD)

Develops NDV-01 for NMIBC and sepranolone for Prader-Willi syndrome.

$4.24
After hours−0.01 (−0.24%)
At close$4.25(+2.16%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
232723192319181010201915
Research & development1015131111111234888
121210812867612117
General & administrative121210812867612117
Operating income−23−27−23−19−23−19−18−10−10−20−19−15
121110100002
Interest income111111000012
Other non-operating income0−2−1−1−10−10000−2
Income before tax−22−25−22−18−22−19−18−10−10−20−19−13
Net income from continuing operations−22−25−22−18−22−19−18−10−10−20−19−13
Net income−22−25−22−18−22−19−18−10−10−20−19−13
EPS, basic−$0.73−$0.84−$0.72−$0.59−$0.72−$0.62−$0.58−$0.30−$0.30−$0.29−$0.22−$0.11
EPS, diluted−$0.73−$0.84−$0.72−$0.59−$0.72−$0.62−$0.58−$0.30−$0.30−$0.29−$0.22−$0.11
Weighted average shares, basic3030303030303033336887112
Weighted average shares, diluted3030303030303033336887112
EBITDA−232−22110−18−10−10−20−19−13
Depreciation & amortization0270192319000000
EBIT−23−25−22−18−22−19−18−10−10−20−19−13